LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference
16 Marzo 2022 - 1:30PM
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a
clinical-stage drug discovery company developing pharmacologically
active drugs for use in cancer treatment, will present at the
MedInvest Pharmaceutical and Biotechnology Investor Conference to
be held March 28 - April 1, 2022. Lixte’s presentation will take
place on Thursday, March 31 at 12:00 - 12:20pm EDT.
Event and Registration: www.medinvestconferences.comDate:
Thursday, March 31 at 12:00 - 12:20pm EDTLocation:
VirtualPresentation: Available livestream and on-demand
LIXTE Founder and CEO John S. Kovach, M.D. will
deliver a company overview as well as an update on LIXTE’s novel,
first-in-class lead clinical compound, LB-100, a PP2A
inhibitor.
About Lixte Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. (Nasdaq:
LIXT), is a clinical-stage pharmaceutical company founded to
identify new targets for cancer drug development. Major drivers of
cancer are defects in the switches that turn the biochemical
pathways in cells on or off. Most cancer research over the past 30
years has focused on the “on” switches because the “off” switches,
especially the master “off” switch protein phosphatase (PP2A), were
believed to cause intolerable toxicity in patients. LIXTE has
achieved a breakthrough with its novel, first-in-class lead
clinical compound and PP2A inhibitor, LB-100, by demonstrating that
LB-100 is readily tolerated in cancer patients at doses associated
with anti-cancer activity. Based on extensive published preclinical
data (see www.lixte.com), LB-100 has the potential
to significantly improve outcomes for patients undergoing various
chemotherapies or immunotherapies. LIXTE’s new approach has no
known competitors and is covered by a comprehensive patent
portfolio. Initial proof-of-concept clinical trials are in
progress.
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission at
www.sec.gov/edgar.shtml
Lixte Contact:info@lixte.comGeneral Phone:
(631) 830-7092Investor Phone: (888) 289-5533
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024